Details of the Drug

General Information of Drug (ID: DMQXI9F)

Drug Name
L-Phenylalanine
Synonyms
Endophenyl; Fenilalanina; Phe; Phenylalanine; Phenylalaninum; Fenilalanina [Spanish]; Phenylalaninum [Latin]; Antibiotic FN 1636; CB 3208; NCI9959; Alpha-Aminohydrocinnamic acid; Beta-Phenylalanine; L-Antibiotic FN 1636; L-PHENYLALININE; N-Formylmelphalan; Phenylalanine (VAN); H-Phe-OH; L-Phenylalanine (JP15); Phenylalanine (USP/INN); Phenylalanine [USAN:INN:JAN]; Beta-Phenyl-L-alanine; N-Formyl-L-sarcolysin; N-Formyl-L-p-sarcolysin; L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl-(9CI); (2S)-2-amino-3-phenylpropanoic acid; (L)-Phenylalanine; (S)-(-)-Phenylalanine; (S)-2-Amino-3-phenylpropanoic acid; (S)-2-Amino-3-phenylpropionic acid; (S)-Phenylalanine; (S)-alpha-Amino-benzenepropanoic acid; (S)-alpha-Amino-beta-phenylpropionic acid; (S)-alpha-Aminohydrocinnamic acid; 1F9436B3-8B0D-4AC6-A004-4249B0BDA436; 3-Phenyl-L-alanine; 3-Phenylalanine; 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
Indication
Disease Entry ICD 11 Status REF
Malnutrition 5B50-5B71 Approved [1], [2]
Therapeutic Class
Dietary supplement
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 165.19
Topological Polar Surface Area (xlogp) -1.5
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is absorbed from the small intestine by a sodium dependent active transport process [3]
Metabolism
The drug is metabolized via the hepatic [3]
Chemical Identifiers
Formula
C9H11NO2
IUPAC Name
(2S)-2-amino-3-phenylpropanoic acid
Canonical SMILES
C1=CC=C(C=C1)C[C@@H](C(=O)O)N
InChI
InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
InChIKey
COLNVLDHVKWLRT-QMMMGPOBSA-N
Cross-matching ID
PubChem CID
6140
ChEBI ID
CHEBI:17295
CAS Number
63-91-2
DrugBank ID
DB00120
TTD ID
D0R1CR
VARIDT ID
DR00266
INTEDE ID
DR2108

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine 3-monooxygenase (TH) TTUHP71 TY3H_HUMAN Binder [4], [5], [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
L-type amino acid transporter 3 (SLC43A1) DTBMSWG LAT3_HUMAN Substrate [7]
L-type amino acid transporter 4 (SLC43A2) DTK02I1 LAT4_HUMAN Substrate [8]
L-type amino acid transporter 2 (SLC7A8) DTJF3DX LAT2_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Phenylalanine--tRNA ligase mitochondrial (FARS2)
Main DME 		DE0WGR8 SYFM_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Malnutrition
ICD Disease Classification 5B50-5B71
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine 3-monooxygenase (TH) DTT TH 9.10E-04 -2.73 -1.55
L-type amino acid transporter 4 (SLC43A2) DTP LAT4 5.91E-01 -1.43E-01 -4.28E-01
L-type amino acid transporter 2 (SLC7A8) DTP LAT2 7.23E-02 -2.92E-01 -4.31E-01
L-type amino acid transporter 3 (SLC43A1) DTP LAT3 9.31E-01 -1.82E-01 -8.57E-01
Phenylalanine--tRNA ligase mitochondrial (FARS2) DME FARS2 1.42E-01 -4.02E-01 -8.90E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3313).
2 Drug information of L-Alanine, Health Canada, 2008. (drugid: 1025)
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
5 Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
6 In situ and in vitro evidence for DCoH/HNF-1 alpha transcription of tyrosinase in human skin melanocytes. Biochem Biophys Res Commun. 2003 Feb 7;301(2):610-6.
7 Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003 Oct 31;278(44):43838-45.
8 Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. J Physiol. 2019 Jan;597(2):521-542.
9 Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.
10 Expression and characterization of a human mitochondrial phenylalanyl-tRNA synthetase. J Mol Biol. 1999 May 14;288(4):567-77.
11 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
12 Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
13 Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
14 Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
15 Clinical pipeline report, company report or official report of Oxford BioMedica.
16 Clinical pipeline report, company report or official report of Oxford BioMedica.
17 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).